Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.1152W HIGH $16.45
Volume
617.09 K
Value Traded
2.88 M
Short % Float
12.5%
Days to Cover
9.9
-1.45%Week
-23.63%1 Month
-21.88%3 Month
-63.35%6 Month
-75.25%5 Year
-75.25%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
184.95 M
EPS (TTM)
-4.26
P/E Ratio
-
Ent. Value
-38.25 M
Total Shares
38.94 M
Float Shares
23.91 M
Insiders
38.60%
Institutions
53.40%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
TRDA Catalyst Timeline
Dated clinical, regulatory and corporate events for Entrada Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Entrada Therapeutics, Inc.
249Total events
15Upcoming
38Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Management ChangeCorporate
Entrada Therapeutics appoints Linea Aspesi as Chief People Officer
▲Secondary Endpoint DataENTR-601-45FiledClinical Data
0.10% mean increase in dystrophin and 0.15% mean increase in exon skipping in Cohort 1
Duchenne Muscular Dystrophy (DMD) amenable to exon 45 skippingsource ↗
▲Safety Data UpdateENTR-601-45FiledClinical Data
Favorable safety profile with no hypomagnesemia or renal safety concerns at 5 mg/kg
Duchenne Muscular Dystrophy (DMD) amenable to exon 45 skippingsource ↗
▲Primary Endpoint MetENTR-601-45FiledClinical Data
Cohort 1 met primary objectives of favorable safety and tolerability at 5 mg/kg
Duchenne muscular dystrophy (exon 45 skipping amenable)source ↗
▲DSMB ReviewENTR-601-44FiledTrial
DMC reviewed Cohort 2 safety/PK data and recommended initiating Cohort 3 at top dose of 18 mg/kg
Duchenne muscular dystrophy (DMD) amenable to exon 44 skippingsource ↗
▲OLE InitiatedENTR-601-45FiledTrial
All Cohort 1 participants progressed to open-label Phase 2 portion
Duchenne muscular dystrophy (exon 45 skipping amenable)source ↗
▲Topline ReadoutENTR-601-45FiledClinical Data
Positive topline results from Cohort 1 (5 mg/kg) of ELEVATE-45-201
Duchenne muscular dystrophy (exon 45 skipping amenable)source ↗
▲Enrollment CompleteENTR-601-45FiledTrial
Cohort 2 enrollment complete; dosing at 10 mg/kg ongoing
Duchenne muscular dystrophy (exon 45 skipping amenable)source ↗
▲Enrollment CompleteENTR-601-44FiledTrial
ELEVATE-44-201 Cohort 2 enrollment complete
Duchenne muscular dystrophy (DMD) amenable to exon 44 skippingsource ↗
▲Grant / FundingCorporate
Entrada announces 2026 DREAMS Grant recipients (PPMD and Duchenne Parent Project Netherlands)
Duchenne muscular dystrophysource ↗
▲Enrollment CompleteENTR-601-44FiledTrial
ELEVATE-44-201 Cohort 2 enrollment complete
Duchenne muscular dystrophy (DMD) amenable to exon 44 skippingsource ↗
▲Enrollment CompleteENTR-601-45FiledTrial
ELEVATE-45-201 Cohort 1 enrollment and dosing completed
Duchenne muscular dystrophy (DMD) amenable to exon 45 skippingsource ↗
▲Dose Finding UpdateENTR-601-45FiledTrial
DMC recommended initiation of Cohort 2 at 10 mg/kg without protocol modification
Duchenne muscular dystrophy (DMD) amenable to exon 45 skippingsource ↗
▲Trial InitiationENTR-601FiledTrial
MHRA and Research Ethics Committee authorization received to initiate ELEVATE-50-201
Duchenne muscular dystrophy (DMD) amenable to exon 50 skippingsource ↗
▲IND SubmissionENTR-601FiledIND
ENTR-601-51 CTA-enabling studies completed
Duchenne muscular dystrophy (DMD) amenable to exon 51 skippingsource ↗
▲Enrollment CompleteVX-670Trial
Vertex completed enrollment in MAD portion of GALILEO
Myotonic dystrophy type 1 (DM1)source ↗
▲Development Candidate NominationENTR-801Preclinical
First ocular candidate ENTR-801 announced for Usher syndrome type 2A
Usher syndrome type 2A (USH2A)source ↗
▲Trial InitiationENTR-601-44FiledTrial
LTE platform study protocol (ENTR-DMD-202) accepted by U.K. and European authorities
Duchenne muscular dystrophy (DMD) amenable to exon 44 skippingsource ↗
▲DSMB ReviewENTR-601-45FiledTrial
DMC recommends initiation of Cohort 2 at 10 mg/kg after review of Cohort 1 safety and PK data
Duchenne muscular dystrophy (DMD) with exon 45 skipping amenablesource ↗
◆Topline ReadoutENTR-601-45FiledClinical Data
Cohort 1 safety, early PK and dystrophin data expected
Duchenne muscular dystrophy (DMD) with exon 45 skipping amenablesource ↗
▼Topline ReadoutENTR-601-44FiledClinical Data
Topline results from Cohort 1 of Phase 1/2 ELEVATE-44-201 study of ENTR-601-44
Duchenne muscular dystrophy amenable to exon 44 skippingsource ↗
◆Oral PresentationENTR-601-44FiledPresentation
Investor webcast and conference call to discuss topline results
Duchenne muscular dystrophysource ↗
▲First Patient DosedENTR-601-44FiledTrial
Initiated dosing of Cohort 2 at 12 mg/kg
Duchenne muscular dystrophysource ↗
▲Enrollment CompleteENTR-601-45FiledTrial
Enrollment completed and dosing initiated in Cohort 1
Duchenne muscular dystrophysource ↗
▲MHRA MilestoneENTR-601FiledEx-US Regulatory
MHRA authorization to initiate Phase 1/2 MAD study
Duchenne muscular dystrophysource ↗
◆Topline ReadoutENTR-601-44FiledClinical Data
Cohort 1 (6 mg/kg) data expected
Duchenne muscular dystrophy (DMD) amenable to exon 44 skippingsource ↗
◆Topline ReadoutENTR-601-45FiledClinical Data
Data from Cohort 1 (5 mg/kg) of ELEVATE-45-201 expected in mid-2026
Duchenne muscular dystrophy (DMD) amenable to exon 45 skippingsource ↗
▲DSMB ReviewENTR-601-44FiledTrial
DMC recommended initiation of Cohort 2 at 12 mg/kg
Duchenne muscular dystrophysource ↗
▲DSMB ReviewENTR-601-44FiledTrial
DMC recommends initiation of Cohort 2 at 12 mg/kg
Duchenne muscular dystrophy (DMD) amenable to exon 44 skippingsource ↗
▲Enrollment CompleteENTR-601-44FiledTrial
Cohort 1 dosing completed in MAD portion
Duchenne muscular dystrophy (DMD) amenable to exon 44 skippingsource ↗
◆Oral PresentationPresentation
Guggenheim Emerging Outlook: Biotech Summit 2026 fireside chat
◆Oral PresentationPresentation
Company presentation at 44th Annual J.P. Morgan Healthcare Conference
▲MHRA MilestoneENTR-601FiledEx-US Regulatory
Regulatory authorization from MHRA and Research Ethics Committee to initiate Phase 1/2 MAD study
Duchenne muscular dystrophy (exon 50 skipping)source ↗
◆Enrollment UpdateENTR-601-44FiledTrial
Planned initiation of study enrollment in first half of 2026
Duchenne muscular dystrophysource ↗
▲Rare Pediatric DiseaseENTR-601-44FiledDesignation
FDA granted Rare Pediatric Disease Designation to ENTR-601-44
Duchenne muscular dystrophy (DMD) amenable to exon 44 skippingsource ↗
▲Development Candidate NominationENTR-801Preclinical
Declared first ocular clinical candidate ENTR-801
Usher syndrome type 2A (USH2A)source ↗
▲First Patient DosedENTR-601-45FiledTrial
First patient dosed in ELEVATE-45-201
Duchenne muscular dystrophysource ↗
▲Other Regulator MilestoneENTR-601FiledEx-US Regulatory
Filed for regulatory authorization in U.K. to initiate ELEVATE-50-201
Duchenne muscular dystrophysource ↗
Past FDA Catalysts and PDUFA Decisions
How TRDA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-14 | ENTR-601-45 | Phase 1/2 topline data readout | Phase 1/2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 38%
Micro Cap(rank 250 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ENTR-601-44 Small moleculeNCT07682129 | Duchenne Muscular Dystrophy (DMD) | Phase 2 | NOT YET_RECRUITING | 104 | Mar 1, 2032 | ||||||
| ENTR-601-45 Small moleculeNCT07038824 | Duchenne Muscular Dystrophy (DMD) | Phase 1 | RECRUITING | 24 | Mar 1, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every TRDA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ENTR-601-45 | Duchenne Muscular Dystrophy | Phase 1/2 | 2026-10-14 | mean increase dystrophin: 0.10%; mean increase exon skipping: 0.15%Read More | Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| MPM BioVentures 2014, L.P.10% Owner | Sell | -28,837 3,885,115 held | $7.13 | 09/09/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TRDA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAKER BROS. ADVISORS | 0.2 % (-50 %) | 37.34 M | 5.07 M |
TRDA Institutional Ownership Trends
TRDA Short Interest
Shares sold short, counted twice a month.
12.5%
Short % of Float
of tradable shares sold short
3.0M
Shares Sold Short
+8.9% vs prior count
9.9 High
Days to Cover
trading days of normal volume to buy every short share back
303.2K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TRDA ranks across every disease it competes in
Competitive Position is a premium feature
See how TRDA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTRDA News
TRDA▼ -6.8%on this news
Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer
Entrada Therapeutics appointed Linea Aspesi as Chief People Officer. Aspesi brings over twenty years of experience in organizational leadership, focusing on culture transformation in biopharmaceutical companies. CEO Dipal Doshi emphasized the importance of a strong team in advancing their neuromuscular programs and delivering genetic medicines to patients.
Read more →TRDA▼ -6.4%on this news
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
Entrada Therapeutics announced positive results from Cohort 1 of the Phase 1/2 ELEVATE-45-201 study for ENTR-601-45 in Duchenne Muscular Dystrophy (DMD) patients. The study met primary safety objectives and showed a mean increase in dystrophin production. Participants will continue to the open-label Phase 2 portion, with further data expected from Cohort 2 in 2027.
Read more →TRDA▼ -6.4%on this news
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
Entrada Therapeutics announced that the independent Data Monitoring Committee has recommended the initiation of Cohort 3 in the ELEVATE-44-201 study at the top dose of 18 mg/kg. This follows the completion of enrollment for Cohort 2, with data expected in Q1 2027. The study evaluates ENTR-601-44 for treating Duchenne muscular dystrophy in eligible patients.
Read more →TRDA▼ -9.7%on this news
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
Entrada Therapeutics announced the recipients of its 2026 DREAMS Grant Program, which awards two $50,000 grants to support projects aimed at improving access for underserved Duchenne muscular dystrophy communities. The selected recipients, Parent Project Muscular Dystrophy and Duchenne Parent Project Netherlands, will utilize the funds to enhance care and resources for individuals living with Duchenne. The grants align with the theme of World Duchenne Awareness Day, focusing on equitable access to healthcare.
Read more →TRDAEntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Entrada Therapeutics has announced the granting of 61,365 restricted stock units and options to purchase 19,425 shares to eight new non-executive employees as part of its 2025 Inducement Equity Plan. The grants, approved by the Compensation Committee, aim to attract talent in accordance with Nasdaq Listing Rule 5635(c)(4). The vesting schedule for these options and RSUs is designed to promote long-term commitment from the new hires.
Read more →TRDAEntrada Therapeutics Reports Second Quarter 2026 Financial Results
Entrada Therapeutics reported its Q2 2026 financial results, highlighting significant upcoming clinical data readouts for its DMD programs. The company is advancing multiple studies, including ELEVATE-44-201 and ELEVATE-45-201, with promising safety and tolerability results. Despite a net loss of $42.8 million, Entrada maintains a strong cash position to support operations through 2027.
Read more →TRDAIndependent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
Entrada Therapeutics announced that the independent Data Monitoring Committee has recommended the initiation of Cohort 2 at an increased dose of 10 mg/kg in the ELEVATE-45-201 study. This decision follows the review of safety and pharmacokinetic data from Cohort 1. The study aims to evaluate the treatment of Duchenne muscular dystrophy with ENTR-601-45, and data from Cohort 1 is expected to be reported in mid-2026.
Read more →TRDAEntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 1, 2026
Entrada Therapeutics has granted 18,600 restricted stock units to three new non-executive employees as part of its 2025 Inducement Equity Plan. This move, approved by the Compensation Committee, aims to incentivize new hires in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over time, contingent on the employees' continued service.
Read more →TRDAMeet Andrew and JJ, living with Duchenne muscular dystrophy Corporate Presentation May 2026 Disclaimer May 2026 2 This presentation has been prepared by Entrada Therapeutics, Inc. (“Entrada”) and shall not
Entrada Therapeutics, Inc. has presented data from a study on ENTR-601-50, a potential treatment for Duchenne muscular dystrophy (DMD), highlighting significant exon skipping and dystrophin restoration in preclinical models. The findings revealed noteworthy improvements in muscle function observed as early as two weeks following a single dose. Entrada is also optimistic that its next-generation exon skippers can effectively target muscle regeneration, providing therapeutic benefits while being safe and flexible for dosing.
Read more →TRDA▼ -57.3%on this newsshared move
Entrada Therapeutics Reports First Quarter 2026 Financial Results
Entrada Therapeutics reported strong financial results for Q1 2026, highlighting positive topline data from the ELEVATE-44-201 study in Duchenne muscular dystrophy. The company has a robust cash position of $255 million, expected to last into Q3 2027. Upcoming data from additional clinical studies is anticipated, marking significant milestones in their neuromuscular pipeline.
Read more →TRDA▼ -57.3%on this newsshared move
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
Entrada Therapeutics announced positive topline results from Cohort 1 of its Phase 1/2 ELEVATE-44-201 study, showing favorable safety and tolerability for ENTR-601-44 in participants with Duchenne muscular dystrophy. The study achieved significant improvements in dystrophin levels and Time to Rise velocity compared to placebo. All participants have progressed to the open-label Phase 2 portion, with expectations for further data by year-end 2026.
Read more →TRDAEntrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
Entrada Therapeutics is set to announce topline results from the first cohort of participants treated with ENTR-601-44 in their Phase 1/2 ELEVATE-44-201 study on May 7, 2026. This double-blind, placebo-controlled study aims to provide insights into the efficacy of their treatment for Duchenne muscular dystrophy. An investor webcast and conference call will follow to discuss the results in detail.
Read more →TRDAEntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 2, 2026
Entrada Therapeutics has announced the grant of 12,990 restricted stock units (RSUs) to two new non-executive employees as part of its 2025 Inducement Equity Plan. This move, approved by the Compensation Committee, aims to incentivize the new hires under Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over a structured timeline, aligning employee retention with company growth.
Read more →TRDA▲ +6.8%on this newsshared move
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Entrada Therapeutics reported a net loss of $143.8 million for the full year 2025. The company held $296 million in cash and equivalents as of December 31, 2025. This balance supports operations through the third quarter of 2027. An independent committee recommended advancing the second cohort of the ELEVATE-44-201 study to a higher dose.
Read more →TRDAIndependent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
Entrada Therapeutics announced that the independent Data Monitoring Committee has recommended the initiation of Cohort 2 at an increased dose of 12 mg/kg in the ELEVATE-44-201 study. Patients from Cohort 1 have progressed to the open label Phase 2 portion, with data from Cohort 1 expected in Q2 2026 and Cohort 2 data by year-end. The study aims to evaluate the treatment of Duchenne muscular dystrophy.
Read more →TRDA▼ -8.2%on this news
Entrada Therapeutics to Present at Upcoming Investor Conferences
Entrada Therapeutics, Inc. (Nasdaq: TRDA) announced its participation in two upcoming investor conferences. CEO Dipal Doshi will engage in fireside chats at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026, and the TD Cowen 46th Annual Health Care Conference on March 3, 2026. Live webcasts will be available on the company's website.
Read more →TRDAEntrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases
Entrada Therapeutics has announced significant progress in its RNA-based programs targeting neuromuscular and ocular diseases. The company is set to report data from its ELEVATE clinical studies for Duchenne muscular dystrophy in 2026 and is expanding its portfolio with a new candidate for Usher syndrome. Additionally, Entrada aims to initiate a Phase 1/2 clinical study for ENTR-601-50 and plans to submit regulatory applications for ENTR-601-51 by the end of 2026. With a strong financial position extending through 2027, Entrada is positioned for continued advancement in its therapeutic development.
Read more →TRDAEntrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Entrada Therapeutics, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. CEO Dipal Doshi will deliver the presentation, which will be available via live webcast and archived for 30 days. The company focuses on developing therapies targeting intracellular mechanisms for various diseases, including neuromuscular and ocular conditions.
Read more →TRDAEntrada Therapeutics Reports Third Quarter 2025 Financial Results
Entrada Therapeutics reported its third quarter 2025 financial results, highlighting progress in its Duchenne muscular dystrophy (DMD) programs. The company is set to deliver data from the ELEVATE-44-201 and ELEVATE-45-201 studies in 2026. Despite a significant net loss and decreased collaboration revenue, Entrada maintains a strong cash position to support its operations into 2027.
Read more →About Entrada Therapeutics, Inc.
HeadquartersONE DESIGN CENTER PLACE, BOSTON, MA, 02210
BIOPHARMAWATCH ELITE PLUS
Trade the next TRDA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime